This article reviews the evolution of the diagnosis and treatment of Hodgkin lymphoma (HL) since its discovery in 1832. The morphological, phenotypic and molecular characteristics of both nodular lymphocyte-predominant HL and classical HL are revised in the light of recent molecular information and possible impact on the identification of risk groups as well as the use of targeted therapies. The seminal contribution of Gianni Bonadonna to developing new treatment strategies for both advanced and early-stage HL is highlighted.
Get full access to this article
View all access options for this article.
References
1.
SwerdlowSCampoEHarrisNWHO classification of tumours of haematopoietic and lymphoid tissues. 4th Edition. Lyon: IARC Press2008.
2.
SwerdlowSHCampoEPileriSAThe 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127 (20):2375–2390.
3.
HodgkinTOn some morbid appearances of the absorbent glands and spleen. Med Chir Trans. 1832;17 (1):68–114.
4.
WilksSEnlargement of the lymphatics glands and spleen (or, Hodgkin's disease) with remarks. Guys Hosp Rep. 1856;11:56.
5.
KüppersRRajewskyKZhaoMHodgkin's disease: clonal Ig gene rearrangements in Hodgkin and Reed-Sternberg cells picked from histological sections. Ann N Y Acad Sci. 1995;764 (1):523–524.
6.
HummelMZiemannKLammertHPileriSSabattiniESteinHHodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells. N Engl J Med. 1995;333 (14):901–906.
7.
MarafiotiTHummelMAnagnostopoulosIOrigin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med. 1997;337 (7):453–458.
8.
HarrisNLJaffeESSteinHA revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84 (5):1361–1392.
9.
LukesRJBJButlerJJThe pathology and nomenclature of Hodgkin's disease. Cancer Res. 1966;26 (6):1063–1083.
10.
FerryJAZukerbergLRHarrisNLFlorid progressive transformation of germinal centers. A syndrome affecting young men, without early progression to nodular lymphocyte predominance Hodgkin's disease. Am J Surg Pathol. 1992;16 (3):252–258.
11.
OsborneBMButlerJJGresikMVProgressive transformation of germinal centers: comparison of 23 pediatric patients to the adult population. Mod Pathol. 1992;5 (2):135–140.
12.
ListerTACrowtherDSutcliffeSBReport of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7 (11):1630–1636.
13.
PrakashSFountaineTRaffeldMJaffeESPittalugaSIgD positive L&H cells identify a unique subset of nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol. 2006;30 (5):585–592.
14.
FanZNatkunamYBairETibshiraniRWarnkeRACharacterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol. 2003;27 (10):1346–1356.
15.
PoppemaSThe nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin's disease. Am J Pathol. 1989;135 (2):351–357.
16.
Nam-ChaSHRoncadorGSanchez-VerdeLPD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma. Am J Surg Pathol. 2008;328: 1252–1257.
17.
AtayarCPoppemaSVisserLvan den BergACytokine gene expression profile distinguishes CD4+/CD57+ T cells of the nodular lymphocyte predominance type of Hodgkin's lymphoma from their tonsillar counterparts. J Pathol. 2006;208 (3):423–430.
18.
MarafiotiTManciniCAscaniSLeukocyte-specific phosphoprotein-1 and PU.1: two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin's disease. Haematologica. 2004;89 (8):957–964.
19.
OhnoTStribleyJAWuGHinrichsSHWeisenburgerDDChanWCClonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med. 1997;337 (7):459–465.
20.
HuppmannARNicolaeASlackGWEBV may be expressed in the LP cells of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in both children and adults. Am J Surg Pathol. 2014;38 (3):316–324.
21.
WlodarskaIStulMDe Wolf-PeetersCHagemeijerAHeterogeneity of BCL6 rearrangements in nodular lymphocyte predominant Hodgkin's lymphoma. Haematologica. 2004;89 (8):965–972.
22.
LisoACapelloDMarafiotiTAberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. Blood. 2006;108 (3):1013–1020.
23.
HartmannSSchuhmacherBRauschTHighly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma. Leukemia. 2016;30 (4):844–853.
LorenziLTabelliniGVermiWOccurrence of nodular lymphocyte-predominant hodgkin lymphoma in Hermansky-Pudlak type 2 syndrome is associated to natural killer and natural killer T cell defects. PLoS ONE. 2013;8 (11):e80131.
26.
StrausSEJaffeESPuckJMThe development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood. 2001;98 (1):194–200.
27.
HartmannSEichenauerDAPlütschowAThe prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2013;122 (26):4246–4252, quiz 4292.
28.
DiehlVSextroMFranklinJClinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol. 1999;17 (3):776–783.
29.
ChittalSMAlardCRossiJFFurther phenotypic evidence that nodular, lymphocyte-predominant Hodgkin's disease is a large B-cell lymphoma in evolution. Am J Surg Pathol. 1990;14 (11):1024–1035.
30.
HansmannMLSteinHFellbaumCHuiPKParwareschMRLennertKNodular paragranuloma can transform into high-grade malignant lymphoma of B type. Hum Pathol. 1989; 20 (12):1169–1175.
GreinerTCGascoyneRDAndersonMENodular lymphocyte-predominant Hodgkin's disease associated with large-cell lymphoma: analysis of Ig gene rearrangements by V-J polymerase chain reaction. Blood. 1996;88 (2):657–666.
33.
WickertRSWeisenburgerDDTierensAGreinerTCChanWCClonal relationship between lymphocytic predominance Hodgkin's disease and concurrent or subsequent large-cell lymphoma of B lineage. Blood. 1995;86 (6):2312–2320.
34.
KhouryJDJonesDYaredMABone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol. 2004;28 (4):489–495.
35.
XingKHConnorsJMLaiAAdvanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. Blood. 2014;123 (23):3567–3573.
36.
AnagnostopoulosIHansmannMLFranssilaKEuropean Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood. 2000;96 (5):1889–1899.
37.
Shimabukuro-VornhagenAHaverkampHEngertALymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials. J Clin Oncol. 2005;23 (24):5739–5745.
38.
ClarkeCAGlaserSLKeeganTHStroupANeighborhood socioeconomic status and Hodgkin's lymphoma incidence in California. Cancer Epidemiol Biomarkers Prev. 2005;14 (6):1441–1447.
39.
ColbyTVHoppeRTWarnkeRAHodgkin's disease: a clinicopathologic study of 659 cases. Cancer. 1982;49 (9):1848–1858.
40.
ColbyTVWarnkeRAThe histology of the initial relapse of Hodgkin's disease. Cancer. 1980;45 (2):289–292.
41.
MacLennanKABennettMHTuARelationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. A study of 1659 patients. Cancer. 1989;64 (8):1686–1693.
42.
WijlhuizenTJVrintsLWJairamRGrades of nodular sclerosis (NSI-NSII) in Hodgkin's disease. Are they of independent prognostic value? Cancer. 1989;63 (6):1150–1153.
43.
MasihASWeisenburgerDDVoseJMBastMAArmitageJOHistologic grade does not predict prognosis in optimally treated, advanced-stage nodular sclerosing Hodgkin's disease. Cancer. 1992;69 (1):228–232.
44.
van SpronsenDJVrintsLWHofstraGCrommelinMACoeberghJWBreedWPDisappearance of prognostic significance of histopathological grading of nodular sclerosing Hodgkin's disease for unselected patients, 197292. Br J Haematol. 1997; 96 (2):322–327.
45.
PileriSAAscaniSLeonciniLHodgkin's lymphoma: the pathologists viewpoint. J Clin Pathol. 2002;55 (3):162–176.
46.
SchwartingRGerdesJDürkopHFaliniBPileriSSteinHBER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood. 1989;74 (5):1678–1689.
47.
SteinHGerdesJKirchnerHSchaadtMDiehlVHodgkin and Sternberg-Reed cell antigen(s) detected by an antiserum to a cell line (L428) derived from Hodgkin's disease. Int J Cancer. 1981;28 (4):425–429.
48.
SteinHMasonDYGerdesJThe expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66 (4):848–858.
49.
PileriSKwongYLTanLHOhshimaKCD30 detection in haematological malignancies: diagnosis and therapeutics. Leuk Res. 2015;39 (3):388.
50.
HsuSMJaffeESLeu M1 and peanut agglutinin stain the neoplastic cells of Hodgkin's disease. Am J Clin Pathol. 1984;82 (1):29–32.
51.
ChittalSMCaverivièrePSchwartingRMonoclonal antibodies in the diagnosis of Hodgkin's disease. The search for a rational panel. Am J Surg Pathol. 1988;12 (1):9–21.
52.
MarafiotiTPozzobonMHansmannMLDelsolGPileriSAMasonDYExpression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease. Blood. 2004;103 (1):188–193.
53.
MathasSJanzMHummelFIntrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol. 2006;7 (2):207–215.
54.
SchweringIBräuningerAKleinULoss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2003;101 (4):1505–1512.
55.
FossHDReuschRDemelGFrequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood. 1999;94 (9):3108–3113.
56.
SchmidCPanLDissTIsaacsonPGExpression of B-cell antigens by Hodgkin's and Reed-Sternberg cells. Am J Pathol. 1991;139 (4):701–707.
57.
LoddenkemperCAnagnostopoulosIHummelMDifferential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol. 2004;202 (1):60–69.
58.
LeonciniLDel VecchioMTMeghaTCorrelations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. Am J Pathol. 1993;142 (3):755–763.
59.
AgostinelliCGallaminiAStracqualursiLThe combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. Lancet Haematol. 2016;3 (10):e467–e479.
60.
RoemerMGAdvaniRHLigonAHPD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34 (23):2690–2697.
61.
DallenbachFESteinHExpression of T-cell-receptor beta chain in Reed-Sternberg cells. Lancet. 1989;2 (8667):828–830.
62.
SeitzVHummelMMarafiotiTAnagnostopoulosIAssafCSteinHDetection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood. 2000;95 (10):3020–3024.
63.
SteidlCLeeTShahSPTumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362 (10):875–885.
64.
TouatiMDelage-CorreMMonteilJCD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment. Leuk Lymphoma. 2015;56 (2):332–341.
65.
TzankovAMatterMSDirnhoferSRefined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology. 2010;77 (6):301–308.
66.
AgurAAmirGPaltielOCD68 staining correlates with the size of residual mass but not with survival in classical Hodgkin lymphoma. Leuk Lymphoma. 2015;56 (5):1315–1319.
67.
AzambujaDNatkunamYBiasoliILack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol. 2012;23 (3):736–742.
68.
RomanoALaura ParrinelloNVetroCThe prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma. Oncotarget. 2016;741: 67333–67346.
69.
SchreckSFriebelDBuettnerMPrognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol. 2009;27 (1):31–39.
70.
TzankovAMeierCHirschmannPWentPPileriSADirnhoferSCorrelation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica. 2008;93 (2):193–200.
71.
DelsolGBroussetPChittalSRigal-HuguetFCorrelation of the expression of Epstein-Barr virus latent membrane protein and in situ hybridization with biotinylated BamHI-W probes in Hodgkin's disease. Am J Pathol. 1992;140 (2):247–253.
72.
HerbstHDallenbachFHummelMEpstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci USA. 1991;88 (11):4766–4770.
73.
LeonciniLSpinaDNyongoANeoplastic cells of Hodgkin's disease show differences in EBV expression between Kenya and Italy. Int J Cancer. 1996;65 (6):781–784.
74.
HummelMAnagnostopoulosIDallenbachFKorbjuhnPDimmlerCSteinHEBV infection patterns in Hodgkin's disease and normal lymphoid tissue: expression and cellular localization of EBV gene products. Br J Haematol. 1992;82 (4):689–694.
75.
WeinrebMDayPJNiggliFThe role of Epstein-Barr virus in Hodgkin's disease from different geographical areas. Arch Dis Child. 1996;74 (1):27–31.
76.
MüschenMRajewskyKBräuningerARare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med. 2000;191 (2):387–394.
77.
KanzlerHKüppersRHansmannMLRajewskyKHodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;184 (4):1495–1505.
78.
MarafiotiTHummelMFossHDHodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000;95 (4):1443–1450.
79.
BräuningerAHansmannMLStricklerJGIdentification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med. 1999;340 (16):1239–1247.
80.
MarafiotiTHummelMAnagnostopoulosIFossHDHuhnDSteinHClassical Hodgkin's disease and follicular lymphoma originating from the same germinal center B cell. J Clin Oncol. 1999;17 (12):3804–3809.
81.
JanzMHummelMTrussMClassical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3), which promotes viability of Hodgkin/Reed-Sternberg cells. Blood. 2006;107 (6):2536–2539.
82.
HinzMLemkePAnagnostopoulosINuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med. 2002;196 (5):605–617.
83.
HinzMLöserPMathasSKrappmannDDörkenBScheidereitCConstitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood. 2001;97 (9):2798–2807.
84.
HöpkenUEFossHDMeyerDUp-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs. Blood. 2002;99 (4):1109–1116.
85.
MathasSJanzMHummelFIntrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol. 2006;7 (2):207–215.
86.
MathasSHinzMAnagnostopoulosIAberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J. 2002;21 (15):4104–4113.
87.
SkinniderBFEliaAJGascoyneRDSignal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2002;99 (2):618–626.
88.
JoosSGranzowMHoltgreve-GrezHHodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int J Cancer. 2003;103 (4):489–495.
89.
MelznerIWenigerMAMenzCKMöllerPAbsence of the JAK2 V617F activating mutation in classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma. Leukemia. 2006;20 (1):157–158.
90.
WenigerMAMelznerIMenzCKMutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene. 2006;25 (18):2679–2684.
91.
Montesinos-RongenMRoersAKüppersRRajewskyKHansmannMLMutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg cells in Hodgkin's disease. Blood. 1999;94 (5):1755–1760.
92.
SchlegelbergerBWeber-MatthiesenKHimmlerACytogenetic findings and results of combined immunophenotyping and karyotyping in Hodgkin's disease. Leukemia. 1994;8 (1):72–80.
93.
JoosSKüpperMOhlSGenomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res. 2000;60 (3):549–552.
94.
KüppersRKleinUSchweringIIdentification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest. 2003;111 (4):529–537.
95.
SavageKJPrimary mediastinal large B-cell lymphoma. Oncologist. 2006;11 (5):488–495.
96.
TiacciEDöringCBruneVAnalyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood. 2012;120 (23):4609–4620.
97.
SteidlCDiepstraALeeTGene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood. 2012;120 (17):3530–3540.
98.
ScottDWChanFCHongFGene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol. 2013;31 (6):692–700.
99.
ReichelJChadburnARubinsteinPGFlow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood. 2015;125 (7):1061–1072.
100.
SteidlCShahSPWoolcockBWMHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471 (7338):377–381.
101.
UrayamaKYJarrettRFHjalgrimHGenome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. J Natl Cancer Inst. 2012; 104 (3):240–253.
102.
JohnsonPCMcAulayKAMontgomeryDModeling HLA associations with EBV-positive and -negative Hodgkin lymphoma suggests distinct mechanisms in disease pathogenesis. Int J Cancer. 2015;137 (5):1066–1075.
103.
HuangXKushekharKNolteIHLA associations in classical Hodgkin lymphoma: EBV status matters. PLoS ONE. 2012;7 (7): e39986.
104.
DevitaVTJrSerpickAACarbonePPCombination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med. 1970;73 (6):881–895.
105.
BonadonnaGZucaliRMonfardiniSDe LenaMUslenghiCCombination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36 (1):252–259.
106.
SantoroABonfanteVBonadonnaGSalvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med. 1982;96 (2):139–143.
107.
SantoroABonadonnaGValagussaPLong-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987;5 (1):27–37.
108.
BonadonnaGChemotherapy strategies to improve the control of Hodgkin's disease: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1982;42 (11):4309–4320.
109.
ValagussaPBonadonnaGHodgkin's disease and the risk of acute leukemia in successfully treated patients. Haematologica. 1998;83 (9):769–770.
110.
VivianiSSantoroARagniGBonfanteVBestettiOBonadonnaGGonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol. 1985;21 (5):601–605.
111.
BonadonnaGValagussaPSantoroAAlternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann Intern Med. 1986;104 (6):739–746.
112.
CanellosGPNiedzwieckiDJohnsonJLLong-term follow-up of survival in Hodgkin's lymphoma. N Engl J Med. 2009;361 (24):2390–2391.
113.
VivianiSBonadonnaGSantoroAAlternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol. 1996;14 (5):1421–1430.
114.
HorningSJRosenbergSAHoppeRTBrief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: an update. Ann Oncol. 1996;7 (Suppl 4):105–108.
115.
GordonLIHongFFisherRIRandomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013;31 (6):684–691.
116.
DiehlVFranklinJPfreundschuhMet al;German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348 (24):2386–2395Erratum in N Engl J Med. 2005;353(7):744. Dosage error in article text.
117.
VivianiSZinzaniPLRambaldiAet al;Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365 (3):203–212.
118.
MerliFLuminariSGobbiPGLong-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol. 2016;34 (11):1175–1181.
119.
CardePKarraschMFortpiedCEight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, international prognostic score ≥ 3, high-risk Hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup Trial. J Clin Oncol. 2016;34 (17):2028–2036.
120.
KellyKMSpostoRHutchinsonRBEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood. 2011;117 (9):2596–2603.
121.
EngertAHaverkampHKobeCet al;German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379 (9828): 1791–1799.
122.
BonadonnaGBonfanteVVivianiSDi RussoAVillaniFValagussaPABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol. 2004;22 (14):2835–2841.
123.
EngertAPlütschowAEichHTReduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363 (7):640–652.
124.
MeyerRMGospodarowiczMKConnorsJMet al;NCIC Clinical Trials Group; Eastern Cooperative Oncology Group. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med. 2012;366 (5):399–408.
125.
GallaminiAHutchingsMRigacciLEarly interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25 (24):3746–3752.
126.
JohnsonPFedericoMKirkwoodAAdapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016;374 (25):2419–2429.
127.
PressOWLiHSchöderHUS Intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816. J Clin Oncol. 2016;34 (17):2020–2027.
128.
ZinzaniPLBroccoliAGioiaDMInterim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol. 2016;34 (12):1376–1385.
129.
GallaminiARossiAPattiCInterim PET adapted chemotherapy in advanced Hodgkin lymphoma. Results of the second interim analysis of the Italian GITIL/FIL HD0607 trial. Hematol Oncol. 2015;33 (Suppl 1)abstr. 118.
130.
RadfordJIllidgeTCounsellNResults of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015;372 (17):1598–1607.
131.
RaemaekersJMAndréMPFedericoMOmitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32 (12):1188–1194.
132.
SpechtLYahalomJIllidgeTet al;ILROG. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89 (4):854–862.
133.
FranciscoJACervenyCGMeyerDLcAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102 (4):1458–1465.
134.
YounesAGopalAKSmithSEResults of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30 (18):2183–2189.
135.
ChenRGopalAKSmithSEFive-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128 (12):1562–1566.
136.
MoskowitzCHNademaneeAMassziTet al;AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385 (9980):1853–1862.
137.
SweetenhamJWWalewskiJNademaneeAUpdated efficacy and safety data from the AETHERA trial of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in Hodgkin lymphoma patients at high risk of relapse. Blood. 2015;126 (3 Suppl):S36–S37.
138.
LaCasceABociekGSawasABrentuximab vedotin plus bendamustine as a salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma. Haematologica. 2016;101 (Suppl 5):45–46.
139.
YounesAConnorsJMParkSIBrentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14 (13):1348–1356.
140.
ConnorsJMAnsellSParkSIBrentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed advanced stage Hodgkin lymphoma: long term outcomes. Blood. 2014;124 (21):292.
141.
BorchmannPEichenauerDAPluetschowATargeted BEACOPP variants in patients with newly diagnosed advanced stage classical Hodgkin lymphoma: final analysis of a randomized phase II study. Blood. 2015;126 (23):580.
142.
AbramsonJSArnasonJELaCasceASBrentuximab vedotin plus AVD for non-bulky limited stage classical Hodgkin lymphoma: a phase 2 trial. Hematol Oncol. 2015;33 (Suppl 1):146.
143.
KumarACasuloCYahalomJBrentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016;128 (11):1458–1464.
144.
YasenchakCAForero-TorresACline-BurkhardtVJMBrentuximab vedotin in combination with dacarbazine or bendamustine for frontline treatment of Hodgkin lymphoma in patients aged 60 years and above: interim results of a multi-cohort phase 2 study. Blood. 2015;126 (23):587.
145.
RotheASasseSToppMSA phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125 (26):4024–4031.
146.
AnsellSMLesokhinAMBorrelloIPD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372 (4):311–319.
JohnstonPBInwardsDJColganJPA Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85 (5):320–324.
149.
Forero-TorresABarrPMDiefenbachCSA phase I study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: interim results from patients with relapsed or refractory classical Hodgkin lymphoma. Hematol Oncol. 2015;33: abstr. 107.
